Hyperoxaluria Therapeutics - Pipeline Analysis , Clinical Trials & Results, Patents, Designations

Hyperoxaluria is a medical condition which involves increased oxalate in urine. The causes of hyperoxaluria include consumption of oxalate-rich foods, intestinal disorders and genetic disorders. The disease is categorized into different types which includes primary hyperoxaluria, enteric hyperoxaluria and hyperoxaluria related to eating high-oxalate foods.

Request to Get the Sample Pages at:  https://www.pharmaproff.com/report/hyperoxaluria-therapeutics-pipeline-analysis

The symptoms observed during hyperoxaluria are severe back pain, blood in urine, frequent urge to urinate, pain when urinating, and fever. The complications associated with the hyperoxaluria includes kidney damage, decreased urine output, loss of appetite, nausea, vomiting, pale skin colour related to anemia and swelling of hands and feet. Hyperoxaluria is treated by using medications, high fluid intake, dietary changes, dialysis and transplantation.

Report Description: https://www.pharmaproff.com/request-sample/1124

Allena Pharmaceuticals Inc. is in the process of developing ALLN-177 as a non-absorbed oral enzyme that specifically degrades oxalate for the treatment of hyperoxaluria. Alnylam Pharmaceuticals Inc., and Dicerna Pharmaceuticals Inc. are some other companies having pipeline drugs for hyperoxaluria. 

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Human Immunodeficiency Virus (HIV) Fusion Inhibitors Therapeutics - Pipeline Analysis, Clinical Trials & Results

Human immunodeficiency virus (HIV) fusion inhibitors is the new class of antiretroviral drugs for the treatment of HIV infections. Failure of combination antiretroviral therapy in patients with HIV, has increased the risk of disease progression. This has led to the development of next generation of fusion inhibitor peptides for better treatment of HIV. Thus, fusion inhibitors have emerged as attractive therapeutics for the treatment of HIV infections.

Request to Get the Sample Pages at:  https://www.pharmaproff.com/request-sample/1202

Studies suggested that HIV fusion inhibitors offers potent antiretroviral activity but its uptake has been limited because of the need for delivery by subcutaneous injection administered twice-daily. Also, chances of cytotoxicity are low in treatment with HIV fusion inhibitors therapeutics as they do not actually enter the cells. Thus, providing many opportunities to the companies for the development of new HIV fusion inhibitors with more potent activity and longer half-lives for better therapeutics with reduced adverse events.

Report Description: https://www.pharmaproff.com/report/hiv-fusion-inhibitors

Frontier Biotechnologies Inc. is in the process of developing Albuvirtide as a treatment-paradigm shifting long-acting HIV fusion inhibitor for treatment of HIV infection. Mapp Biopharmaceutical Inc., and United Biomedical Inc. are some other companies having pipeline of HIV fusion inhibitors.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

Read More

Tau Protein Inhibitors Therapeutics - Pipeline Analysis , Clinical Trials & Results, Patents, Designations

Tau protein is found in abundance in neurons of the central nervous system. This protein is a product of microtubule-associated protein tau (MAPT) gene, that is located on chromosome 17. It is associated with pathologies of several nervous system disorders, such as dementia, Parkinson’s disease, and Alzheimer’s disease.

Request to Get the Sample Pages at: https://www.pharmaproff.com/request-sample/1199

The main function of the protein is to stabilize microtubules. There are six isoforms of the protein present in the brain tissue which can be distinguished by their number of binding domains. The advancements in the protein by hyperphosphorylation and aggregation are observed in a molecular study of the disease.

Report Description:

https://www.pharmaproff.com/report/tau-protein-inhibitors-therapeutics

AC Immune SA is developing a number of tau proteins inhibitor molecules. Neurimmune Holding AG is also in the process of developing BIIB076 as a tau protein inhibitor, for the treatment of Alzheimer’s disease. ProMIS Neurosciences Inc. is another company developing tau proteins.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Prader-Willi Syndrome – Epidemiology Insights

Prader-Willi syndrome (PWS) is a complicated genetic condition which can affect various parts of the body. During infancy, this condition is identified by weak muscle tone (hypotonia), problems in feeding, poor growth, and delay in development.

Request to Get the Sample Pages at:  

https://www.pharmaproff.com/request-sample/1163

It begins in childhood due to which the patients develop an insatiable appetite, which can result in chronic overeating (hyperphagia) and obesity. Few patients with PWS, especially those who are obese, also develop type 2 diabetes. Some common symptoms of this disease are floppiness, learning difficulties, behavioral problems, restricted growth, and excessive appetite or loss of appetite.

Report Description:

https://www.pharmaproff.com/report/prader-willi-syndrome

PWS is a common form of obesity and affects about 350,000 and 400,000 individuals worldwide. It affects males and females in equal ratio and occurs in all ethnic groups and regions in the world.

The report covers historical and forecast epidemiology of the disease in the seven major markets including the U.S., EU5 (France, Germany, Italy, Spain, U.K.), and Japan. The report has been compiled by building an understanding of the disease, after reviewing numerous studies conducted by regulatory bodies in various countries.

Read More…

Read More

Glaucoma – Epidemiology Insights

Glaucoma can be described as a group of diseases characterized by cupping of the optic nerve head and visual-field damage. These diseases differ from each other in terms of their causes, risk factors, demographics, symptoms, duration, treatment, and prognosis.

Report Description:

https://www.pharmaproff.com/report/glaucoma-epidemiology-forecast

The common identifiable features for all forms of glaucoma are loss of retinal ganglion cells, thinning of the retinal nerve fiber layer, and cupping of the optic nerve. There are two key categories of glaucoma; open-angle glaucoma (OAG), and narrow angle glaucoma.

Request to Get the Sample Pages at:  

https://www.pharmaproff.com/request-sample/1159

Glaucoma is mainly associated with old age and its overall prevalence is found to be significantly lower in regions with young population. The epidemiological studies have reported that the global prevalence of glaucoma is approximately 3.5% for people aged 40-80 years.

The report covers historical and forecast epidemiology of the disease in the seven major markets including the U.S., EU5 (France, Germany, Italy, Spain, U.K.), and Japan. The report has been compiled by building an understanding of the disease, after reviewing numerous studies conducted by regulatory bodies in various countries.

Read more..

Read More

Hyperkalemia Therapeutics - Pipeline Analysis , Clinical Trials & Results, Patents, Designations, Collaborations

Hyperkalemia is referred to as increased levels of potassium in blood which results in cardiac arrest and death. Potassium levels above 5.1 mEq/l are considered as the hyperkalemia condition. The main causes of hyperkalemia are potassium sifting out of cells into the blood circulation, adrenal gland diseases, kidney dysfunction, uncontrolled diabetes, breakdown of muscle tissue and red blood cells.

Access Detailed Report Summary: https://www.pharmaproff.com/report/hyperkalemia-therapeutics-pipeline-analysis

Hyperkalemia causes abnormal heart rhythms and also interferes in the functioning of the skeletal muscles. The common symptoms associated with the hyperkalemia are fatigue, nausea, muscle weakness and tingling sensations.

Request to Get the Sample Pages at: https://www.pharmaproff.com/request-sample/1155

The standard treatment strategies for hyperkalemia are intravenous administration of glucose and insulin, a diet low in potassium, medications that stimulate beta-2 adrenergic receptors, sodium bicarbonate administration and discontinue medications that increase blood potassium levels. Ardelyx Inc. is developing RDX013 which acts as a potassium secretagogue for the treatment of hyperkalemia. Relypsa Inc. is another key player involved in the development of drugs for the treatment of hyperkalemia.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Wiskott-Aldrich Syndrome Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations

Wiskott-Aldrich syndrome is a hereditary immunodeficiency disorder characterized by abnormal functioning of immune system and decreased ability to form blood clots. The abnormality in the platelets leads to easy bruising effects in case of prolonged bleeding.

The white blood cells become non-functional and cause other immunological disorders in Wiskott-Aldrich syndrome. It has been discovered that this disease is caused by the mutation in WAS gene (Xp11.4-p11.21) that instruct to make Wiskott-Aldrich syndrome protein. Some of the symptoms observed in the patients are thrombocytopenia, hematologic abnormalities, eczema, and malignancies.

Request to Get the Sample Pages at: https://www.pharmaproff.com/request-sample/1152

Genethon Inc. is in the process of developing autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene as a gene therapy for the treatment of Wiskott-Aldrich syndrome. Further, the University of Pittsburgh and Orchard Therapeutics Limited are also involved in the pipeline for Wiskott-Aldrich syndrome.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More..

Read More

Vaginitis Therapeutics - Pipeline Analysis , Clinical Trials & Results, Patents, Designations, Collaborations

Vaginitis refers to the inflammation of vagina. It affects women of all ages but is most common during the reproductive years. Vaginitis occurs due to change in the balance of the yeast and bacteria that normally live in the vagina.

Access Detailed Report Summary: https://www.pharmaproff.com/report/vaginitis-therapeutics-pipeline-analysis

This causes the lining of the vagina to become inflamed. Use of antibiotics, changes in hormone levels due to pregnancy, breastfeeding, menopause, douching, spermicides, sexual intercourse and infection can change the normal balance of the vagina. The main symptom of vaginitis is increased discharge with a strong fishy odour. Itching is not common, but may be present if there is a lot of discharge.

Request to Get the Sample Pages at:  https://www.pharmaproff.com/request-sample/1151

Vaginitis can be diagnosed by taking a sample of the discharge from vagina, which is then observed under a microscope. The treatment depends on the cause of the vaginitis. It may include a pill or a cream or gel that is applied to the vagina.

The drug candidates in vaginitis pipeline include, but are not limited to, Polygynax and Tamoxifen vaginal. Some of the companies in vaginitis therapeutics pipeline are Lumavita AG and Fulhold Pharma Limited.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More..

Read More

Uterine Fibroids Therapeutics - Pipeline Analysis , Clinical Trials & Results

Uterine fibroids, also known as leiomyomas or myomas, are non-cancerous growths that develop from the muscle tissue of the uterus. The size, shape, and location of fibroids can vary greatly. They may be present inside the uterus on its outer surface, or within its wall, or attached to it by a stem-like structure.

Access Detailed Report Summary: https://www.pharmaproff.com/report/uterine-fibroids-therapeutics-pipeline-analysis

A fibroid may remain very small for a long time and suddenly grow rapidly, or grow slowly over a number of years. It usually affects women between the age of 30 to 40 years, but can occur at any age. Uterine fibroids may have various symptoms, such as change in menstruation, anaemia, abdominal cramps, constipation, pain during sex, rectal pain, and difficulty urinating or frequent urination. It is diagnosed through ultrasonography, hysteroscopy, hysterosalpingography, and sonohysterography. Some medications are known to reduce heavy bleeding and painful periods, caused due to this condition.

Request to Get the Sample Pages at: https://www.pharmaproff.com/request-sample/1150

The drug candidates in uterine fibroids disease pipeline include, but are not limited to, Elagolix, OBE2109, and Proellex. Some of the companies having drugs in the uterine fibroids disease pipeline are Neurocrine Biosciences Inc., Abbvie Inc., and ObsEva SA.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Turner Syndrome Therapeutics - Pipeline Analysis , Clinical Trials & Results, Patents, Designations

Turner syndrome is a chromosomal condition, which occurs when one of the two X chromosomes normally found in women is missing or incomplete. The disease alters the growth and development in females. The symptoms can vary among women who have Turner syndrome. Women with this condition tend to be shorter than average and are usually unable to conceive a child because of an absence of ovarian function.

Access Detailed Report Summary: https://www.pharmaproff.com/report/turner-syndrome-therapeutics-pipeline-analysis

Some other features of this condition are extra skin on the neck (webbed neck), heart defects and kidney problems, puffiness or swelling (lymphedema) of the hands and feet, and skeletal abnormalities. This condition occurs in about one in 2,500 female births worldwide, but is much more common among pregnancies that do not survive to term (miscarriages and stillbirths).

Request to Get the Sample Pages at:  https://www.pharmaproff.com/request-sample/1149

The drug candidates of Turner syndrome disease pipeline include, but are not limited to are Estradiol and Somatropin pegylated. Some of the companies having drugs in the Turner syndrome disease pipeline are Novo Nordisk A/S, GeneScience Pharmaceuticals Co. Ltd., and Polus Inc.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Reperfusion Injury Therapeutics - Pipeline Analysis , Clinical Trials & Results, Patents, Designations

Reperfusion injury is the damage to tissues caused when blood supply returns to the tissue after a period of ischemia or lack of oxygen (anoxia, hypoxia). It influences the patient’s outcome after myocardial infarction, stroke, cardiovascular surgery, and organ transplantation.

Access Detailed Report Summary:

https://www.pharmaproff.com/report/reperfusion-injury-therapeutics-pipeline-analysis

The treatments available for reperfusion injury are therapeutic hypothermia, hydrogen sulfide treatment, cyclosporin, stem cell therapy and metformin. Radikal Therapeutics Inc. is in the process of developing R-190 as an intravenous formulation for the treatment of limb ischemia reperfusion injury. The drug candidate is being developed as a small molecule which acts as a nitric oxide donors and reactive oxygen species inhibitor. Some of the companies having a pipeline of reperfusion injury include Catalyst Biosciences Inc., MIFCOR Inc. and others.

Request to Get the Sample Pages at:  https://www.pharmaproff.com/request-sample/1148

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More..

Read More

Post-Operative Nausea and Vomiting Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations

Post-operative nausea and vomiting is one of the complications of anaesthesia given to the patients at the time of a surgery. The state of having unpleasant sensation subjected to desire of vomiting is known as nausea whereas, vomiting is the forceful expulsion contents present in gastrointestinal tracts.

Access Detailed Report Summary:

https://www.pharmaproff.com/report/post-operative-nausea-and-vomiting-therapeutics-pipeline-analysis

The chemoreceptor trigger zone, vagal mucosal pathway, neuronal pathway, reflex afferent pathway, and midbrain afferent pathway are responsible for the stimulation of vomiting. These pathways stimulate histaminergic, cholinergic, and dopaminergic receptors to activate the sensation of vomiting. In the postrema region, neurokinin-1 receptors are present which also play an important role in emesis (action of vomiting).

Request to Get the Sample Pages at:  

Camurus AB is in the process of developing CAM2058 as a serotonin 3 receptor antagonist for the treatment of post-operative nausea and vomiting. Some of the companies and universities having the pipeline of post-operative nausea and. Further, universities like the University of British Columbia and Assiut University are also involved in the pipeline for post-operative nausea and vomiting.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More..

Read More

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results

Mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome, is a progressive disorder that primarily affects brain and spinal cord (central nervous system). People with MPS III generally do not display features at birth, but they begin to show signs and symptoms of this disorder during early childhood. Affected children often initially have delayed speech and behaviour problems. In later stages of this disorder, people with MPS III may develop seizures and movement disorders.

Access Detailed Report Summary: https://www.pharmaproff.com/report/mps-iiitherapeutics-pipeline-analysis

Patients with MPS III are also known to have short stature, joint stiffness, or mild dysostosis multiplex. Affected individuals often experience chronic diarrhoea and recurrent upper respiratory and ear infections. People with MPS III may also have hearing loss and vision problems. MPS III is divided into four types; IIIA, IIIB, IIIC, and IIID, which are distinguished by their genetic cause.

Request to Get the Sample Pages at:  

The drug candidates in MPS III pipeline include, but are not limited to, EGT-101, MPS IIIA (Sanfilippo A) Program and LYS-SAF302. Some companies having drugs in the MPS III pipeline are Esteve Pharmaceuticals S.A., Orchard Therapeutics Limited, Lysogene S.A. among others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More..

Read More

Viral Bronchiolitis Therapeutics - Pipeline Analysis , Clinical Trials & Results, Patents, Designations

Viral bronchiolitis is an inflammatory disorder which is characterized by obstruction of small airways, necrosis and edema of the epithelial cells, and increased mucus production. The disease is most commonly caused by an infection caused by respiratory syncytial virus.

Access Detailed Report Summary:

https://www.pharmaproff.com/report/viral-bronchiolitis-therapeutics-pipeline-analysis

The signs and symptoms observed in the patients are low grade fever, congestion, and apnea. However, in most severe cases, respiratory distress, cyanosis, and irritability also occurs in the patients. Viral bronchiolitis is the most common illness observed in children in their first two years of life.

Request to Get the Sample Pages at:

  

Ait Therapeutics Inc. is in the process of developing AIT-RSV as a guanylate cyclase stimulant for the treatment of viral bronchiolitis. Some of the other companies and universities having pipeline drugs for viral bronchiolitis include Washington University School of Medicine, and Vaxart Inc.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read more…

Read More

Pleural Effusion Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results

Pleural effusion is the fluid build-up in the pleural space and is categorized into two types which includes exudate and transudate. Transudate is usually composed of ultrafiltrates of plasma due to heart failure or cirrhosis; while, exudate is caused by inflammatory conditions. The major causes of pleural effusion are kidney failure, infection, congestive heart failure, malignancy, pulmonary embolism, cirrhosis, hypoalbuminemia and trauma.

The common symptoms associated with the pleural effusion are chest pain, difficulty in breathing, painful breathing, cough, fever and loss of appetite. The standard treatments available for pleural effusion are thoracentesis, surgery, antibiotics and diuretics.

Request to Get the Sample Pages at:  

Lung Therapeutics Inc. is in the process of developing LTI-01 as a single chain urokinase plasminogen activator for the treatment of safe clearance of fibrinous scar tissue in patients with loculated pleural effusion. Genelux Corporation is another key player involved in the development of drugs for the management of pleural effusion.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More..

Read More

Interstitial Lung Disease Therapeutics - Pipeline Analysis

interstitium of the lungs. The interstitium is a lace like network of the tissue that provide support to the air sacs and the capillaries in the interstitium which allows the gas exchange between the blood and alveolar tissues.

Some of the types of the condition include interstitial pneumonia, idiopathic pulmonary fibrosis, and non-specific interstitial pneumonitis. Major symptoms associated with the disease include dry cough and shortness of breath.

Request to Get the Sample Pages at:  

Regend Therapeutics is in the process of developing lung stem cells as a cell therapy for the treatment of interstitial lung disease. Boehringer Ingelheim GmbH is in the process of developing nintedanib as a fibroblast growth factor receptor antagonist for the treatment of this medical condition.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More..

Read More

Nav1.7 Voltage-Gated Sodium Channel Inhibitors Therapeutics - Pipeline Analysis

Nav1.7 voltage-gated sodium channel inhibitors are the drug candidates that target the sodium channels Nav1.7 and have been significant in pain management. The sodium channels Nav1.7 receptors are generally found in two types of neurons: nociceptive pain neurons, such as trigeminal neurons and dorsal root ganglion; and sympathetic ganglion neurons which form a part of the autonomic (involuntary) nervous system. These receptors play an important role in generation and conduction of action potential.

The sodium channels Nav1.7 is generally encoded by SCN9A gene. Voyager Therapeutics Inc. is developing VY-NAV01 as a Nav1.7-voltage-gated-sodium-channel-inhibitor for the treatment of severe and chronic pain. Sumitomo Dainippon Pharma Co. Ltd. is in the process of developing DSP-2230 as a Nav1.7 and Nav1.8 voltage-gated-sodium-channel-inhibitor for the treatment of neuropathic pain. Some of the companies having the pipeline of Nav1.7 voltage-gated sodium channel inhibitors include Xenon Pharmaceuticals Incorporated, SiteOne Therapeutics Inc., Icagen Inc. and others.

Request to Get the Sample Pages at:  

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More..

Read More

RNA Interference (RNAi) Therapeutics - Pipeline Analysis , Clinical Trials & Results

RNA interference (RNAi) is a molecule type that silences the gene and limits the transcription of the mutated gene. Gene silencing is a novel mechanism that inactivates the transcripts of mutated gene, by activating sequence specific RNA degradation process. The process of RNAi is also known as post-transcriptional gene silencing. This novel mechanism holds potential to revolutionize the biological science for escaping out the disease.

The drug candidate acts upon double stranded DNA or double stranded RNA. There are several applications of RNAi in various areas, such as gene knockdown, functional genomics, medicine, biotechnology, and genome scale screening. In medicine, the therapeutic candidate can be used for the treatment of virus-related disease and cancer, whereas, in biotechnology, this novel mechanism can help in the production of transgenic plants and nutrient enriched food.

Request to Get the Sample Pages at:  

Dicerna Pharmaceuticals Inc. is developing a wide range of next generation RNAi therapies in clinical and non-clinical stages of development. Some of the companies having pipeline of RNAi therapies include Silence Therapeutics plc, Arrowhead Research Corporation Inc., and Phio Therapeutics Corp.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More…

Read More

Rho Kinase Inhibitor Therapeutics - Pipeline Analysis , Clinical Trials & Results, Patents, Designations, Collaborations

Rho kinase inhibitor, also known as ROCK inhibitor, inhibits the rho kinases, a family of small GTP-binding protein. Rho kinases are found to regulate cell motility, proliferation, shape, gene expression, apoptosis, and are also involved in the signalling pathway. The inhibition of rho kinases has shown some beneficial effects in cardiovascular diseases, including systemic hypertension, vasospastic angina, stable effort stigma, pulmonary hypertension, stroke, and heart failure.

Rho kinases are a member of serine/threonine kinases and are encoded by ROCK1 and ROCK2 gene. There are many evidences that show rho kinase inhibitors play a significant role in improving symptoms related to cardiovascular diseases, as it has been experimentally proven that rho kinase gets upregulated in the cardiovascular disorders. The development of inhibitors of rho kinase isoforms can be an advantage, inclined to the specificity of the cardiovascular disorders. In addition, the pathophysiology of other disorders, such as intracerebral hemorrhage, diabetes, Parkinson’s disease, and Alzheimer’s disease are related to the modulation of rho kinases.

Request to Get the Sample Pages at: 

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More…

Read More

p53 Antigen Modulators Therapeutics - Pipeline Analysis, Clinical Trials & Results, Patents, Designations

p53 is the tumor suppressor transcription factor that activates to various stimulus, including uncontrolled cell proliferation, oncogene over-expression, and DNA damage. p53 antigen modulators helps in preventing cancer development through regulation of cell cycle and apoptosis. Thus, new opportunities in cancer immunotherapy are expected to develop better drug candidates targeting p53, with complete understanding of interactions between p53 and the immune system, to avoid various adverse events. The major challenge is prevention of tissue damage by selectively modulating p53 activity, under pathophysiological conditions that generate redox stress.

p53 antigen modulator therapies are being widely studied for the development of various target specific cancer therapies. Dendritic cell-derived vaccines, adenoviral p53 vectors, MDM2 inhibitors and small-molecules to reinstate the DNA binding activity of p53 are some commercial approaches as p53 antigen modulator therapies, for the treatment of various indications. Also, research studies have demonstrated that novel therapeutic strategies are being developed to overcome the challenges related to in-depth knowledge of p53 and associated pathways.

Request to Get the Sample Pages at:  

Quark Pharmaceuticals Inc. is developing QPI-1002 as a nuclease-resistant, synthetic double-stranded RNA oligonucleotide designed to temporarily inhibit the expression of the pro-apoptotic gene p53, for the treatment of delayed graft function and acute kidney injury. Some of the companies having a therapeutic pipeline of p53 antigen modulators include Innovation Pharmaceuticals Inc., Aprea Therapeutics, and Actavalon Inc.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

Read More..

Read More

Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) Inhibitor Therapeutics - Pipeline Analysis , Clinical Trials & Results

Cytotoxic T-lymphocyte antigen-4 (CTLA-4) plays important role in the T-cell regulation at an early stage of naive T-cell activation, primarily in the lymph nodes. CTLA-4 has emerged as an attractive cancer immunotherapy as a part of “immune checkpoint blockade”. CTLA-4 pathway inhibitors enhance T-cell activation and amplify T-cell proliferation. Successful results of immune checkpoint inhibitors in cancer immunotherapy has led to the development of many new agents and strategies, including combination for the treatment of various cancers.

Despite of many advancements in the development of anti-cancer therapies, cancer is still one of the major causes of deaths, globally. Combination therapies are proving to be more efficient than monotherapy for the treatment of cancer. Studies have demonstrated that concurrent PD-1 and CTLA-4 blockade have shown positive results in patients with advanced melanoma. This provides huge opportunities for development of better combinatorial immunotherapeutic therapies for checkpoint blockade with molecular targeted therapies, angiogenesis inhibition and novel vaccines.

Request to Get the Sample Pages at:  

Agenus Inc. is in the process of developing AGEN1884 as a monoclonal antibody which acts as a CTLA-4 inhibitor for the treatment of non-small cell lung cancer. It is also being studied in combination with pembrolizumab, for the treatment of cancer. Some of the other companies having pipeline of CTLA-4 inhibitor include AstraZeneca PLC, ​ImmunOs Therapeutics AG, Tikcro Technologies Ltd.

Read More..

Read More

Cyclophilin Inhibitors Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations

Cyclophilin befits in the group of protein that shows peptidyl-prolyl cis-trans isomerase activity, found in all types of cells. In humans, 16 cyclophilins have been identified till date. Cyclophilin A, a member of cyclophilin group, mediate the action of immunosuppressive drugs. A ternary complex is formed when cyclophilin A interact with another cyclosporin A and inhibits calcineurin protein that regulates cytokine gene transcription. 

Cyclophilin A is involved in trafficking of proteins that distributes action of asialoglycoprotein receptor between plasma membrane and endosomal pool; promotes nuclear export; and translates neuronal nuclei to induce cell death in various pathological conditions which includes amyotrophic lateral sclerosis and cerebral hypoxia-ischemia. In addition, cyclophilin plays important role in cell signalling. Cyclophilin D is located in mitochondria and regulates the opening of mitochondrial permeability transition pore. Cyclophilins are involved in pathophysiology of neurodegenerative diseases.

Request to Get the Sample Pages at:  

Several companies, such as Ensemble Therapeutics, Debiopharm Group, and ContraVir Pharmaceuticals Inc., are actively involved in the development of cyclophilin inhibitors therapeutics. For instance, Ensemble Therapeutics is in the process of developing a drug candidate that acts as a cyclophilin antagonist for the treatment of Parkinson’s disease, amyotrophic lateral sclerosis, and hepatitis B. Debiopharm Group is developing Debio 025 cyclophilin inhibitor for the treatment of muscular dystrophy. Moreover, ContraVir Pharmaceuticals Inc. is also developing CRV431 as a cyclophilin antagonist for the treatment of hepatitis B.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More..

Read More

Cell Cycle Inhibitors Therapeutics - Pipeline Analysis , Clinical Trials and Results Report

Cell cycle inhibitors include cyclin inhibitors and cyclin-dependent kinases (CDKs), which plays major role in developing new class of anti-cancer therapies. Also, cell cycle inhibitors in combination with chemotherapy, overcome drug resistance and improve cytotoxic efficacy. CDKs are rational targets for cancer treatment, that could restore cell-cycle checkpoints and may induce apoptosis.

Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematologic and oncologic disorders, developing alvocidib - a potent CDK9 inhibitor in combination with cytarabine and daunorubicin. In April 2018, the company presented preclinical data supporting the apoptosis-inducing activity of alvocidib at the American Association for Cancer Research (AACR) Annual Meeting in the U.S., Chicago.

Request to Get the Sample Pages at:  

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

Read More…

Read More

Androgen Receptor Antagonist Therapeutics - Pipeline Analysis, Clinical Trials & Results

Androgens are responsible for the development of male characteristics by binding to androgen receptors. Androgen receptor plays an important role in the development and progression of prostate cancer. Thus, it has been an attractive target for the clinical interventions and treatment of prostate cancer. This has led to the development of new therapies for the better treatment of castration-resistant prostate cancer.

Several studies have demonstrated the promising results of cancer immunotherapy with androgen receptor antagonists for the treatment of prostate cancer. Androgen receptor antagonists with immunotherapy enhanced the immune response and prevent the relapse of advanced prostate cancer. Thus, providing many opportunities to the companies for the development of combination therapies of androgen receptor antagonists with immunotherapy for the treatment of prostate cancer.

Request to Get the Sample Pages at:

Taiho Pharmaceutical Co. Ltd. is in the process of developing TAS3681 as a novel oral androgen receptor antagonist with dual mechanism of action, acting as both an androgen receptor antagonist and a down-regulator of androgen receptor, for the treatment of prostate cancer. Pfizer Inc., Eisai Co., Ltd., and Evgen Pharma Limited are some other companies having pipeline of androgen receptor antagonist.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

Read More..

Read More

Androgen Receptor Antagonist Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents

Androgens are responsible for the development of male characteristics by binding to androgen receptors. Androgen receptor plays an important role in the development and progression of prostate cancer. Thus, it has been an attractive target for the clinical interventions and treatment of prostate cancer. This has led to the development of new therapies for the better treatment of castration-resistant prostate cancer.

Several studies have demonstrated the promising results of cancer immunotherapy with androgen receptor antagonists for the treatment of prostate cancer. Androgen receptor antagonists with immunotherapy enhanced the immune response and prevent the relapse of advanced prostate cancer. Thus, providing many opportunities to the companies for the development of combination therapies of androgen receptor antagonists with immunotherapy for the treatment of prostate cancer.

Request to Get the Sample Pages at:  

Taiho Pharmaceutical Co. Ltd. is in the process of developing TAS3681 as a novel oral androgen receptor antagonist with dual mechanism of action, acting as both an androgen receptor antagonist and a down-regulator of androgen receptor, for the treatment of prostate cancer. Pfizer Inc., Eisai Co., Ltd., and Evgen Pharma Limited are some other companies having pipeline of androgen receptor antagonist.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others

Read More..

Read More

Alpha-Synuclein Inhibitor Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations

Alpha-synuclein is a protein that is abundantly found in the brain. The minimal amount of alpha-synuclein is also found in the heart and other tissues. The protein is prominently found at the tips of the nerve cells. It helps in the maintaining supply of the synaptic vesicle in presynaptic terminals.

In addition, the alpha-synuclein protein also helps in release of dopamine. The protein comprised of 140 amino acids and is encoded by Synuclein Alpha (SNCA) gene. It produced mostly in hippocampus, neocortex, substantia nigra, and cerebellum. However, the actual function of alpha-synuclein is still completely unknown. However, the pathophysiology of Parkinson’s disease is associated with the accumulation of alpha-synuclein protein which forms Lewy bodies.

Request to Get the Sample Pages at:  

F. Hoffmann-La Roche Ltd. is in the process of developing RG7935 as a monoclonal antibody targeting alpha-synuclein, for the treatment of Parkinson’s disease. AC Immune SA is in the process of developing morphomer α-syn as an alpha-synuclein inhibitor for the treatment of Parkinson’s disease. Neuropore Therapies Inc. is also developing a drug candidate that targets alpha-synuclein, for the treatment of Parkinson’s disease and multiple system atrophy.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More..

Read More

Dasatinib - Drug Insight Insights, Potential Business Strategies, Mergers and Acquisitions, Revenue Analysis

Dasatinib (Sprycel) medicines are generally used to treat people with chronic myeloid leukemia and people with acute lymphoblastic leukemia who have been tested positive for the Philadelphia chromosome (Ph+). Developed by Bristol-Myers Squibb Company, Dasatinib has been approved by the FDA for the treatment of pediatric patients aged one-year-old with newly diagnosed Ph+ acute lymphoblastic leukemia in combination with chemotherapy. The clinical trials have shown positive results with increased safety and efficacy. The most common side-effects of Dasatinib in children with chemotherapy include swelling, pain, fever, nausea, and diarrhea.

The report provides a comprehensive understanding of the drug, covering all the API manufactures and its details in the 7 major markets which includes EU5 (U.K., Spain, Germany, Italy and France), U.S., and Japan. It covers all patents and strategic developments reported in this drug area. It highlights the historical and forecasted sales along with the market scenario, market competition and the historical and emerging therapies. The report is inclusive of SWOT and PESTLE analysis, depending on the information availability.

Request to Get the Sample Pages at:  

Moreover, the report also provides a comprehensive understanding of the pipeline activities of the drug candidate under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drug by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology and others.

Read More..

Read More